Neuronetics (STIM)

Executive Summary

Neuronetics is a commercial-stage medical device company pioneering non-invasive neuromodulation therapies for psychiatric disorders. Its flagship product, NeuroStar Advanced Therapy, is a transcranial magnetic stimulation (TMS) system FDA-cleared for major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and anxious depression. With a growing body of clinical evidence and increasing awareness of TMS as a treatment alternative, Neuronetics is well-positioned to capture share in the large addressable market of patients with treatment-resistant depression and other psychiatric conditions. The company's focus on expanding indications and improving patient access through favorable reimbursement policies underpins its growth strategy. Financially, Neuronetics has demonstrated steady revenue growth driven by system placements and recurring consumables sales. The company benefits from a recurring revenue model as installed base customers purchase maintenance and disposable components. Although facing competition from other TMS players and emerging neuromodulation technologies, Neuronetics' established brand, proprietary coil design, and comprehensive clinical data provide competitive advantages. With a valuation of approximately $142 million and shares outstanding of 69.6 million, the stock offers an attractive entry point for investors seeking exposure to the mental health technology space. Upcoming catalysts include potential label expansions and strategic partnerships that could accelerate adoption.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance for bipolar depression indication60% success
• Q2 2027Positive topline results from pivotal trial for PTSD50% success
• Q4 2026Expansion of Medicare coverage for TMS in OCD70% success